Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 10/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903518 | 0.77 | PTK2 (0.56) | PTK2NPC1RAB9AGRM5DPP4 | |
| SCHEMBL9903399 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL9902702 | 0.75 | PTK2 (0.48) | PTK2MAPTNPC1RAB9AGRM5 | |
| SCHEMBL9903802 | 0.73 | GRM5 (0.49) | PTK2GRM5DPP4 | |
| SCHEMBL9903792 | 0.72 | PTK2 (0.50) | PTK2NPC1RAB9AGRM5DPP4 | |
| SCHEMBL1872354 | 0.72 | ALDH1A1 (0.59) | PTK2ALDH1A1MAPTGAATDP1 | |
| SCHEMBL1427022 | 0.70 | ALDH1A1 (0.57) | PTK2ALDH1A1MAPTGAATDP1 | |
| SCHEMBL16913907 | 0.69 | HPGD (0.54) | ALDH1A1MAPTGAATDP1NPC1 | |
| SCHEMBL12850740 | 0.68 | PTK2 (0.52) | PTK2MAPTNPC1RAB9AHPGD | |
| SCHEMBL21865284 | 0.68 | PTK2 (0.52) | PTK2MAPTNPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | PTK2 3720/4885ALDH1A1 3284/4885MAPT 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.